CD19 and primary central nervous system lymphoma: also reported five patients with CNS lymphoma (one patient with PCNSL and four patients with secondary CNS lymphoma) who underwent anti-CD19 and CD22 cocktail CAR-T cell therapy with a follow-up of 6-16 months.